ActRIIA Kinase Activity Inhibitor Screening Kit: A Core Tool from Signal Pathway Analysis to Targeted Drug Discovery

Author: Senior Product Manager of UA Views：14

This article systematically elaborates on the molecular characteristics of ActRIIA as a TGF-β superfamily receptor and its core functions in muscle growth, metabolic regulation, and tissue fibrosis, centered on the technical principles and application systems of the ActRIIA kinase activity inhibitor screening kit. It analyzes the critical role of kinase activity detection in ActRIIA-targeted drug screening and explores the application strategies of the inhibitor screening kit in compound activity evaluation and structure-activity relationship studies.

Recent Advances
Product Information

Recent Advances

ActRIIA Kinase Activity Inhibitor Screening Kit: A Core Tool from Signal Pathway Analysis to Targeted Drug Discovery

Brief Introduction: This article systematically elaborates on the technical principles and application systems of the ActRIIA kinase activity inhibitor screening kit, detailing the molecular characteristics of ActRIIA as a TGF-β superfamily receptor and its core functions in muscle growth, metabolic regulation, and tissue fibrosis. It analyzes the critical role of kinase activity detection in ActRIIA-targeted drug screening and explores the application strategies of inhibitor screening kits in compound activity evaluation and structure-activity relationship studies.

1. Molecular Characteristics and Signal Transduction Mechanism of ActRIIA

Activin receptor type IIA is a type I single-pass transmembrane protein encoded by the ACVR2A gene, belonging to the serine/threonine kinase receptor family of the transforming growth factor-β (TGF-β) superfamily. This gene is located on human chromosome 2q22.3, and the encoded receptor protein consists of an extracellular ligand-binding domain, a single transmembrane helix region, and an intracellular serine/threonine kinase domain. ActRIIA can bind with high affinity to multiple ligands of the TGF-β superfamily, including activin A, activin B, myostatin, and growth differentiation factor 11. Upon ligand binding, ActRIIA undergoes conformational changes and dimerizes, subsequently recruiting and phosphorylating type I receptors, activating the downstream SMAD2/3 signaling pathway, and ultimately regulating the transcription of target genes.

ActRIIA is widely distributed in tissues, expressed in bones, blood vessels, immune cells, and various organs, participating in diverse physiological processes. In muscle tissue, ActRIIA and ActRIIB jointly mediate myostatin signaling, playing a negative regulatory role in maintaining muscle mass. In the skeletal system, ActRIIA signaling regulates the balance between bone formation and resorption. In the vascular system, ActRIIA is involved in blood vessel development and repair. In the immune system, ActRIIA influences immune cell differentiation and function. These diverse physiological functions make ActRIIA an important therapeutic target in multiple disease areas.

2. Technical Principles of ActRIIA Kinase Activity Detection

The intracellular kinase domain of ActRIIA possesses serine/threonine kinase activity, which is the core step in signal transduction and a key target for small-molecule inhibitors and antibody-based drugs. The essence of ActRIIA kinase activity detection lies in quantitatively measuring the progress of phosphorylation reactions. When ActRIIA is incubated with its substrate in the presence of ATP, the kinase catalyzes the transfer of the terminal phosphate group from ATP to serine or threonine residues on the substrate protein, generating one molecule of ADP for each ATP consumed. Therefore, by quantitatively detecting the amount of ADP generated, the catalytic activity of the kinase can be indirectly reflected.

The ActRIIA kinase activity inhibitor screening kit typically employs a coupled enzyme chemiluminescence detection system. The detection process involves two key steps: first, an ATP removal reagent is added to terminate the kinase reaction and eliminate interference from residual ATP; then, an ADP detection reagent is added to convert the generated ADP back into ATP, producing a bioluminescent signal proportional to the ADP concentration through the luciferase/luciferin system. This design establishes a precise quantitative relationship between luminescence intensity and kinase activity, with detection sensitivity reaching the picomolar level. By plotting the dose-response curve between compound concentration and kinase activity inhibition rate, the half-maximal inhibitory concentration (IC50) can be calculated to quantitatively evaluate the inhibitory activity of candidate compounds.

3. Technical Advantages of the ActRIIA Inhibitor Screening Kit

The ActRIIA kinase activity inhibitor screening kit offers multiple technical advantages in drug discovery. In terms of high sensitivity, the kit can quantitatively detect extremely low levels of ADP generation, making it suitable for low-activity kinases and low-concentration compound detection. In substrate compatibility, the kit supports various substrate types, including peptides and proteins, meeting the needs of different experimental systems. In ATP concentration adaptability, the kit is compatible with a wide range of ATP concentrations, from low micromolar to high millimolar levels, allowing researchers to determine inhibitor competition types by adjusting ATP concentrations.

In operational convenience, the kit adopts a "add-mix-detect" homogeneous operation mode, eliminating the need for washing or separation steps, and is compatible with high-throughput formats such as 96-well and 384-well plates. In signal stability, the optimized "glow-type" luminescent signal has a half-life of several hours, supporting batch processing and flexible time windows. In data reproducibility, the Z-factor typically exceeds 0.7, meeting the requirements of high-throughput screening for data reproducibility. Additionally, this method is unaffected by compound fluorescence interference, making it suitable for screening various chemical libraries.

4. Application Strategies of the ActRIIA Inhibitor Screening Kit

The ActRIIA kinase activity inhibitor screening kit is integral to multiple key stages of targeted drug discovery. In compound screening, the kit can be used to establish high-throughput screening platforms, identifying lead compounds with ActRIIA inhibitory activity from large-scale compound libraries. In structure-activity relationship studies, systematically measuring the IC50 values of a series of compounds can reveal patterns between compound structure and activity, guiding structural optimization.

In mechanism of action studies, changing ATP concentrations can determine the competition type of inhibitors—competitive inhibitors exhibit lower IC50 values at low ATP concentrations, while non-competitive inhibitors' IC50 values are unaffected by ATP concentration. In selectivity evaluation, the kit can be used to assess compound selectivity for ActRIIA versus other TGF-β family receptors (e.g., ActRIIB), reducing potential off-target effects. In combination therapy studies, it can evaluate the synergistic effects of ActRIIA inhibitors with inhibitors of other pathways.

In experimental design, the following key factors should be considered. The concentrations of ActRIIA kinase domain protein and substrate should be optimized to ensure the detection system operates within the optimal linear range. ATP concentration and reaction time should be standardized based on ActRIIA kinase characteristics. Positive and negative controls are recommended to validate the effectiveness of the experimental system. For different compound libraries, appropriate buffer systems can be selected based on their chemical properties.

5. Conclusion

In the practical application of ActRIIA kinase activity inhibitor screening, high-quality detection reagents are key to ensuring data reliability and experimental reproducibility. To meet the needs of ActRIIA-targeted drug screening, Uni offers the ActRIIA Enzyme Activity Inhibitor Screening Kit. This product is based on an optimized coupled enzyme chemiluminescence detection system and features the following core characteristics: high sensitivity for quantitatively detecting extremely low levels of ADP generation, suitable for screening low-activity kinase inhibitors; excellent substrate compatibility for various substrate types, including peptides and proteins; broad ATP concentration compatibility to distinguish competitive and non-competitive inhibitors; homogeneous operation mode without washing or separation steps, compatible with high-throughput formats such as 96-well and 384-well plates; stable "glow-type" luminescent signals supporting flexible time windows. This kit is suitable for applications such as ActRIIA inhibitor screening and structure-activity relationship analysis, kinase activity regulation mechanism research, and TGF-β superfamily signaling pathway studies.

As a key receptor in the TGF-β superfamily, ActRIIA, with its multiple functions in muscle growth, metabolic regulation, and tissue fibrosis, has become a highly promising drug target in multiple disease areas. The ActRIIA kinase activity inhibitor screening kit provides an efficient and reliable detection platform for ActRIIA-targeted drug discovery, playing an indispensable supporting role from compound screening to mechanism studies, from structure-activity relationship analysis to selectivity evaluation. The ActRIIA Enzyme Activity Inhibitor Screening Kit offers a reliable tool for ActRIIA inhibitor screening, continuously driving innovation in drug development for this target.

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Nanjing Univ is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UNIV Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

The Last The Next